A use patent related to Redasemutide for fatty liver\/NASH is scheduled to be registered in Australia. The impact does not directly affect near-term results but secures the possibility of indication expansion. There is no impact on full-year results for the fiscal year ending July 2027.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4599","jir_company_name":"StemRIM","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-11-09","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4599-20261109-02.pdf","jir_short_summary":"A use patent related to Redasemutide for fatty liver\/NASH is scheduled to be registered in Australia. The impact does not directly affect near-term results but secures the possibility of indication expansion. There is no impact on full-year results for the fiscal year ending July 2027.","jir_summary":"### Key Points\nThis announcement concerns the registration of a use patent in Australia for treatment of fatty liver and non-alcoholic steatohepatitis (NASH). The patent relates to therapeutic use of the regenerative induction pharmaceutical candidate Redasemutide (development code: S-005151), with applicants StemRIM, Osaka University, and Niigata University. At present, there is no impact on full-year results for the fiscal year ending July 2027, and patent grant secures the possibility of development in Australia. Uncertainties include that the registration number is not yet determined.\n\n### Impact on Investors and Future Outlook\nWhile the potential for new therapeutic areas accompanying indication expansion is acknowledged, the current disclosure does not specify financial effects. In the long term, indication expansion for Redasemutide could enhance the value of the company's R&D portfolio, but this information does not directly affect recent earnings. If disclosure items arise following notice of patent grant, they will be published promptly.","jir_financial_highlights":"Revenue: Unknown (Unknown)\nOperating Income: Unknown (Unknown)\nNet Income: Unknown (Unknown)","jir_category":"","jir_hashtags":"#StemRIMDisclosure, #PatentRegistration, #PharmaceuticalDevelopmentNews","jir_key_figures":"Patent Filing Region: Australia\nApplication Number: 2021466375\nRegistration (Publication) Number: TBD","jir_meta_title":"StemRIM: Notice of Australian Patent Registration for Fatty Liver\/NASH Therapeutic Use\uff5cNovember 2026","jir_meta_description":"StemRIM announces Australian patent registration for Redasemutide-related use in fatty liver and NASH. Applicants include Osaka University and Niigata University. No impact on FY ending July 2027. Monitor future developments.","jir_og_title":"StemRIM: Australian Patent Registration for Fatty Liver Therapeutic Use\uff5cNovember 2026","jir_og_description":"A use patent for Redasemutide in fatty liver\/NASH is scheduled to be registered in Australia. The impact does not directly affect near-term results; further disclosures are pending.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":58113,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"disclosure_update","footnotes":""},"sector":[],"importance":[],"class_list":["post-145547","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n